Cetus Proleukin
Executive Summary
Orphan status for treatment of renal cell carcinoma granted by FDA. Cetus, which has been studying the recombinant interleukin-2 product in a number of cancers, says it will file a Proleukin PLA before 1989, but has not disclosed what claims it will seek. Roche, which is developing an Immunex IL-2 product, is also near the PLA submission stage and, like Cetus, has not publicly announced what indications it is interested in. However, at a recent analyst meeting, Immunex Chairman Stephan Duzan noted that the best clinical responses of IL-2 have been observed in renal cell carcinoma and melanoma.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.